XML 42 R24.htm IDEA: XBRL DOCUMENT v3.5.0.2
Marketable Securities and Fair Value Measurements (Tables)
9 Months Ended
Sep. 30, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Financial assets and liabilities measured at fair value on a recurring basis
The following table presents the Company’s assets and liabilities that are measured at fair value on a recurring basis, and are determined using the following inputs as of September 30, 2016:
 
 
Fair Value Measurements at
 
September 30, 2016
 
Total
 
Quoted Prices
in Active Markets
(Level 1)
 
Significant
Other Unobservable
Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
Assets:
 
 
 
 
 
 
 
Money market funds
$
13,778,470

 
$
13,778,470

 
$

 
$

Mutual funds
70,235,667

 

 
70,235,667

 

US corporate debt securities
26,199,918

 

 
26,199,918

 

Investments in affiliated entities
25,296,348

 
25,296,348

 

 

Total Assets
$
135,510,403

 
$
39,074,818

 
$
96,435,585

 
$

Liabilities:
 
 
 
 
 
 
 
Common stock warrants
$
1,812,502

 
$

 
$

 
1,812,502

Total Liabilities
$
1,812,502

 
$

 
$

 
$
1,812,502


The following table presents the Company’s assets and liabilities that are measured at fair value on a recurring basis, and are determined using the following inputs as of December 31, 2015:
 
 
Fair Value Measurements at
 
December 31, 2015
 
Total
 
Quoted Prices
in Active Markets
(Level 1)
 
Significant
Other Unobservable
Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
Assets:
 
 
 
 
 
 
 
Money market funds
$
54,474,609

 
$
54,474,609

 
$

 
$

Mutual funds
78,385,992

 

 
78,385,992

 

US corporate debt securities
26,869,403

 

 
26,869,403

 

Municipal bonds
101,882

 

 
101,882

 

Investment in affiliated entities
19,987,192

 
19,987,192

 

 

Common stock warrants
5,970

 

 

 
5,970

Total Assets
$
179,825,048

 
$
74,461,801

 
$
105,357,277

 
$
5,970

Liabilities:
 
 
 
 
 
 
 
Common stock warrants
$
1,301,138

 
$

 
$

 
$
1,301,138

Total Liabilities
$
1,301,138

 
$

 
$

 
$
1,301,138

Assumptions used to estimate the fair values of the common stock warrants
The assumptions used to estimate the fair value of common stock warrants at September 30, 2016 are presented below:
 
Risk-free interest rate
0.73%
Expected volatility
60%
Expected life in years
2.0
Dividend yield
Change in fair value of the financial assets
The following table presents a summary of changes in fair value of the Company’s total Level 3 financial assets for the nine months ended September 30, 2016:
Balance at January 1, 2016
$
5,970

Decrease in fair value included in change in fair value of common stock warrants
(5,970
)
Balance at September 30, 2016
$


Changes in fair value of the financial liabilities
The following table presents the changes in fair value of the Company’s total Level 3 financial liabilities for the nine months ended September 30, 2016:
 
Balance at January 1, 2016
$
1,301,138

Increase in fair value included in change in fair value of common stock warrants
511,364

Balance at September 30, 2016
$
1,812,502

OncoSec [Member]  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Assumptions used to estimate the fair values of the common stock warrants
The assumptions used to estimate the fair values of the OncoSec common stock warrant at September 30, 2016 are presented below:

Risk-free interest rate
0.43%
Expected volatility
88%
Expected life in years
0.5
Dividend yield